Join us for a webinar exploring how LiquidHALLMARK®, a cutting-edge liquid biopsy test, is transforming cancer care.

Diagnostic advances allow earlier & more accurate detection of Alzheimer's using cerebrospinal fluid biomarkers.

Register now – Nov. 12, 2025 - PACE/State of FL - Review known genetic predisposing factors to acute or chronic pancreatitis, as well as define who may benefit from genetic testing.

The following cases are designed for healthcare professionals interested in understanding the assessment and treatment options for patients with systemic lupus erythematosus disease.

In this episode of Mayo Clinic Laboratories’ “Leveraging the Laboratory” podcast, host Jane Hermansen, outreach manager at Mayo Clinic Laboratories, is joined by colleagues Ellen Dijkman Dulkes and Brianne Newton to discuss building an outreach team.

In this episode of “Answers From the Lab,” William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, is joined by Russ Lebovitz, M.D., Ph.D., CEO and co-founder of Amprion. They discuss their strategic collaboration and the innovative SAAmplify™–αSYN (CSF) test.

In the first quarter of 2025, Mayo Clinic Laboratories expanded its test catalog with several innovative new tests.

Medical Laboratory Professionals Week is a time to appreciate the profound impact of laboratory medicine on healthcare and innovation.

Communication is a critical component of success. Laboratory outreach leaders can foster truly effective communication with five simple steps.

Learn why threshold diagnoses of the breast are important, how to approach them, and what role technology might play in the future.

PACE/State of FL - Negotiating, maintaining and monitoring payer agreements.

Paul Jannetto, Ph.D., explains how Mayo Clinic Laboratories' SPAS test identifies the form of arsenic present in patients with arsenic exposure. That information is important for determining the potential level of harm and for removing the patient from the arsenic source to ease symptoms and prevent cancer risk.

By using a test that measures neurofilament light chain (Nfl) proteins in blood, clinicians can better diagnose devastating diseases like ALS and MS, help predict disease progression, and better assess efficacy of existing drugs and trial therapies.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss the recent court judgment on the U.S. Food and Drug Administration’s (FDA) oversight of lab-developed tests (LDT).

PACE/State of FL - The role of cytology specimens in molecular genetic testing, emphasizing their effectiveness in identifying biomarkers critical for targeted therapies in patients with cancer.